| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
60,512 |
56,089 |
$5.04M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,868 |
31,286 |
$1.78M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
3,686 |
3,593 |
$753K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
4,356 |
4,142 |
$721K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
11,846 |
11,617 |
$679K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
10,404 |
10,056 |
$594K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
26,595 |
25,515 |
$562K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
18,848 |
18,105 |
$513K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
8,598 |
8,431 |
$489K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
28,070 |
26,902 |
$335K |
| 87634 |
|
6,333 |
5,587 |
$298K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,250 |
3,162 |
$189K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,682 |
3,594 |
$171K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
16,411 |
15,436 |
$152K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
3,670 |
3,591 |
$129K |
| 96127 |
|
24,655 |
23,550 |
$122K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,737 |
4,586 |
$117K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,582 |
2,470 |
$112K |
| 90670 |
|
4,830 |
4,729 |
$105K |
| 87581 |
|
3,695 |
3,595 |
$96K |
| 87486 |
|
3,696 |
3,596 |
$96K |
| 87640 |
|
4,504 |
4,365 |
$94K |
| 87498 |
|
3,693 |
3,595 |
$78K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
909 |
879 |
$72K |
| 99173 |
|
18,245 |
17,842 |
$72K |
| 90461 |
|
1,326 |
1,278 |
$70K |
| 92551 |
|
15,198 |
14,863 |
$66K |
| 90680 |
|
3,210 |
3,158 |
$62K |
| 99215 |
Prolong outpt/office vis |
477 |
458 |
$62K |
| 81003 |
|
21,308 |
20,536 |
$60K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
442 |
428 |
$56K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
6,578 |
6,471 |
$54K |
| 90698 |
|
2,646 |
2,584 |
$51K |
| 90686 |
|
2,491 |
2,455 |
$48K |
| 90671 |
|
1,597 |
1,593 |
$42K |
| 90633 |
|
2,160 |
2,118 |
$42K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,012 |
933 |
$41K |
| 90697 |
|
1,963 |
1,947 |
$39K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,720 |
2,597 |
$31K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
221 |
208 |
$28K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,427 |
3,255 |
$26K |
| D1206 |
Topical application of fluoride varnish |
1,166 |
1,141 |
$25K |
| 94010 |
|
1,196 |
1,138 |
$24K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
837 |
804 |
$19K |
| 90744 |
|
903 |
879 |
$17K |
| 92567 |
|
1,188 |
1,115 |
$13K |
| 83655 |
|
710 |
687 |
$10K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
168 |
158 |
$8K |
| 94664 |
|
889 |
860 |
$7K |
| 90656 |
|
335 |
333 |
$7K |
| 86308 |
|
1,150 |
1,110 |
$7K |
| 90734 |
|
83 |
81 |
$5K |
| 90651 |
|
108 |
107 |
$5K |
| 90685 |
|
238 |
237 |
$5K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
153 |
152 |
$4K |
| 87641 |
|
173 |
171 |
$4K |
| 87500 |
|
173 |
171 |
$4K |
| D0145 |
Oral evaluation for a patient under three years of age |
109 |
107 |
$2K |
| 90688 |
|
125 |
125 |
$2K |
| 99000 |
|
591 |
577 |
$2K |
| 85018 |
|
754 |
742 |
$2K |
| 90710 |
|
90 |
88 |
$2K |
| 94060 |
|
61 |
60 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
140 |
132 |
$2K |
| 90696 |
|
75 |
74 |
$1K |
| 69210 |
|
65 |
60 |
$1K |
| 90619 |
|
66 |
63 |
$1K |
| 90716 |
|
49 |
49 |
$969.71 |
| 90707 |
|
49 |
49 |
$969.71 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
602 |
576 |
$889.01 |
| 88720 |
|
148 |
92 |
$748.98 |
| 36416 |
|
281 |
275 |
$558.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
46 |
45 |
$533.24 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
42 |
40 |
$496.77 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
16 |
16 |
$402.88 |
| 82947 |
|
107 |
102 |
$394.94 |
| 90715 |
|
12 |
12 |
$237.48 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
374 |
369 |
$200.95 |
| 87339 |
|
12 |
12 |
$132.00 |
| 99050 |
|
45 |
44 |
$41.78 |
| 96160 |
|
41 |
40 |
$41.66 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
1,967 |
1,921 |
$4.21 |
| 94760 |
|
248 |
238 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
256 |
254 |
$0.00 |